Ipsen: Initiation of Phase III Clinical Trials with Decapeptyl(R)'s 4-Month Sustained Release Formulation.PARIS Paris, in Greek mythology
Paris or Alexander, in Greek mythology, son of Priam and Hecuba and brother of Hector. Because it was prophesied that he would cause the destruction of Troy, Paris was abandoned on Mt. -- Ipsen (Paris:IPN IPN Instant Payment Notification (PayPal)
IPN Instituto Politecnico Nacional (México)
IPN Infectious Pancreatic Necrosis
IPN Interplanetary Internet (JPL) ) (Euronext:FR0010259150) announced today that the 4-month sustained release formulation of Decapeptyl([R]), originated from the Group's internal research, is being tested in a phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the . This new formulation, aimed at improving patients' quality of life, is based on Ipsen's proprietary drug delivery system technology and uses the Group's advanced drug delivery platform. This development is part of the life-cycle management strategy for the products of Ipsen research and development pipeline.
Decapeptyl([R]) is a formulation for injection of a peptide analogue of GnRH (triptorelin) that was initially developed and continues to be used mainly in the treatment of advanced metastatic Metastatic
The term used to describe a secondary cancer, or one that has spread from one area of the body to another.
Mentioned in: Coagulation Disorders
pertaining to or of the nature of a metastasis. prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. . In addition, Decapeptyl([R]) is also indicated in the treatment of uterine fibroids Uterine Fibroids Definition
Uterine fibroids (also called leiomyomas or myomas) are benign growths of the muscle inside the uterus. They are not cancerous, nor are they related to cancer. (a benign tumour of muscle tissues in the uterus), endometriosis endometriosis (ĕn'dəmē'trē-ō`sĭs), a condition in which small pieces of the endometrium (the lining of the uterus) migrate to other places in the pelvic area. (proliferation of endometrial endometrial /en·do·me·tri·al/ (en?do-me´tre-il) pertaining to the endometrium.
n relating to the end-ometrium or cavity of the uterus. tissue, the mucous membrane mucous membrane
A membrane lining all body passages that communicate with the exterior, such as the respiratory, genitourinary, and alimentary tracts, and having cells and associated glands that secrete mucus. Also called mucosa. that lines the uterine wall outside the reproductive tract), prior to surgery or when surgery is not deemed appropriate, as well as early-onset puberty and female infertility (in vitro fertilisation).
Decapeptyl([R]) is available in monthly or quarterly sustained-release formulations, as well as a daily formulation.
Decapeptyl([R]) has marketing authorisations in over 60 countries, including 25 in Europe; it was launched in Great Britain in 2003 (quarterly formulation) and in Germany during 2004 (under the Pamorelin([R]) brand).
In 2005, 67.1% of Decapeptyl([R]) sales of a total amount of [euro]210.6 million derived from the major Western European countries. For the first nine months of 2006, sales of Decapeptyl([R]) reached [euro]168.4 million, up 5.7% compared to the first nine months of 2005.
Oncology is one of the main targeted therapeutic areas of the Ipsen Group, with endocrinology and neuromuscular disorders. Its peptide and protein engineering and medicinal chemistry platforms enable it to explore and develop new approaches in cancer treatment under hormonal control. These research programmes are conducted internally with assistance from university and industry specialists.
About innovative delivery technologies
Ipsen is one of the world leaders in sustained-release delivery systems with two peptides currently marketed, triptorelin (Decapeptyl([R])) and lanreotide (Somatuline([R])and Somatuline([R])Autogel([R])). Further to Decapeptyl([R])'s research programmes, the Group is also pursuing pre-clinical development of sustained-release formulations of Somatuline([R]) Autogel([R]) for longer treatment duration than the one already marketed (28 days). In addition, Ipsen signed a R&D agreement with Genentech in November 2004, which covers the development of sustained-release formulations of recombinant human growth hormone human growth hormone (HGH): see growth hormone. . Moreover, under its agreement with Roche, Ipsen is studying an innovative, user-friendly sustained release formulation of BIM BIM Building Information Modeling
BIM Building Information Model
BIM Bord Iascaigh Mhara (Irish Sea Fisheries Board)
BIM Brussels Instituut voor Milieubeheer (Belgium)
BIM Bharathidasan Institute of Management 51077, GLP-1 analogue, for type 2 diabetic patients.
Ipsen is a European pharmaceutical group with over 20 products on the market and a total worldwide staff of nearly 4,000. The Company's development strategy is based on a combination of products in targeted therapeutic areas (oncology, endocrinology and neuromuscular disorders), which are growth drivers and primary care products which contribute significantly to its research financing. This strategy is also supported by an active policy of partnerships. The location of its four R&D centers (Paris, Boston, Barcelona and London) gives the Group a competitive edge in gaining access to leading university research teams and highly qualified personnel. In 2005, Research and Development expenditure reached [euro]169 million, i.e. 20.9% of consolidated sales, which amounted to [euro]807 million in the Group's pro forma accounts set up according to the IFRS IFRS International Financial Reporting Standard(s)
IFRS Inter Frame Relay Service
IFRS Indiana Facilities Registry System . Nearly 700 people in R&D are dedicated to the discovery and development of innovative drugs for patient care. Ipsen's shares are traded on Segment A of Eurolist by Euronext (stock code: IPN, ISIN Isin (ĭs`ĭn), capital of an ancient Semitic kingdom of N Babylonia. The city became important after the third dynasty of Ur fell to the Elamites and the Amorites (c.2025 B.C.). The phase from c.2025–c.1763 B.C. code: FR0010259150). Ipsen's internet website is www.ipsen.com.
The forward-looking statements and targets contained herein are based on Ipsen's management's current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein.
Ipsen expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based unless so required by applicable law. Ipsen's business is subject to the risk factors outlined in its information documents filed with the French Autorite des marches financiers.